JEFFREY YORDON - 03 Aug 2022 Form 4 Insider Report for Athenex, Inc. (ATNX)

Role
COO, and President, Athenex Pharmaceutical Division.
Signature
/s/Staci Holquist, Attorney-in-Fact
Issuer symbol
ATNX
Transactions as of
03 Aug 2022
Transactions value $
-$2,127
Form type
4
Filing time
15 Aug 2022, 17:34:39 UTC
Previous filing
21 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNX Common Stock Options Exercise +12,500 +5.3% 249,606 03 Aug 2022 Direct F1
transaction ATNX Common Stock Tax liability -$2,126 -3,663 -1.5% $0.5806 245,943 03 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNX Restricted Stock Units Options Exercise $0 +12,500 +50% $0 37,500 03 Aug 2022 Common Stock 12,500 Direct F1, F5
holding ATNX Stock Option (Right to Buy) 150,000 03 Aug 2022 Common Stock 150,000 $9 Direct
holding ATNX Stock Option (Right to Buy) 211,820 03 Aug 2022 Common Stock 211,820 $11 Direct
holding ATNX Stock Option (Right to Buy) 100,000 03 Aug 2022 Common Stock 100,000 $17.3 Direct
holding ATNX Stock Option (Right to Buy) 100,000 03 Aug 2022 Common Stock 100,000 $13.17 Direct F2
holding ATNX Stock Option (Right to Buy) 100,000 03 Aug 2022 Common Stock 100,000 $12.45 Direct F3
holding ATNX Stock Option (Right to Buy) 50,000 03 Aug 2022 Common Stock 50,000 $3.8 Direct F4
holding ATNX Stock Option (Right to Buy) 150,000 03 Aug 2022 Common Stock 150,000 $0.6655 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of stock.
F2 This option vests in four equal annual installments beginning on February 28, 2020.
F3 This option vests in four equal annual installments beginning on June 5, 2021.
F4 This option vests in four equal annual installments beginning on August 3, 2022.
F5 The restricted stock units vest in four equal annual installments beginning on August 3, 2022.
F6 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

COO, and President, Athenex Pharmaceutical Division.